Literature DB >> 23302636

MicroRNA 210 as a biomarker for congestive heart failure.

Kosuke Endo1, Yukiko Naito, Xu Ji, Michio Nakanishi, Teruo Noguchi, Yoichi Goto, Hiroshi Nonogi, Xiao Ma, Huachun Weng, Go Hirokawa, Takashi Asada, Sachiro Kakinoki, Tetsuji Yamaoka, Yasue Fukushima, Naoharu Iwai.   

Abstract

MicroRNAs (miRNAs) are endogenous small RNAs that are 18-23 nucleotides long. Recently, plasma miRNAs were reported to be sensitive and specific biomarkers of various pathological conditions. In the present study, we focused on miR-210, which is known to be induced by hypoxia and might therefore be an excellent biomarker for congestive heart failure. Plasma miR-210 levels and expression levels in mononuclear cells and skeletal muscles were elevated in Dahl salt-sensitive rats with heart failure. We also assessed miR-210 expression in patients with heart failure. The miR-210 expression levels in the mononuclear cells of patients with NYHA III and IV heart failure according to the New York Heart Association (NYHA) functional classification system were significantly higher than those with NYHA II heart failure and controls. Although no significant correlation was observed between plasma brain natriuretic peptide (BNP) and plasma miR-210 levels in patients with NYHA II heart failure, patients with an improved BNP profile at the subsequent hospital visit were classified in a subgroup of patients with low plasma miR-210 levels. Plasma miR-210 levels may reflect a mismatch between the pump function of the heart and oxygen demand in the peripheral tissues, and be a new biomarker for chronic heart failure in addition to plasma BNP concentrations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23302636     DOI: 10.1248/bpb.b12-00578

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  44 in total

1.  An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells.

Authors:  Andrew Hale; Changjin Lee; Sofia Annis; Pil-Ki Min; Reena Pande; Mark A Creager; Colleen G Julian; Lorna G Moore; S Alex Mitsialis; Sarah J Hwang; Stella Kourembanas; Stephen Y Chan
Journal:  Biochim Biophys Acta       Date:  2014-06-28

2.  Serum miR-146a, miR-155, and miR-210 as potential markers of Graves' disease.

Authors:  Lei Zheng; Chunbo Zhuang; Xiaobei Wang; Liang Ming
Journal:  J Clin Lab Anal       Date:  2017-05-31       Impact factor: 2.352

3.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

4.  Elevated levels of miR-210 correlate with anemia in β-thalassemia/HbE patients.

Authors:  Panjaree Siwaponanan; Suthat Fucharoen; Pornpan Sirankapracha; Pranee Winichagoon; Tsukuru Umemura; Saovaros Svasti
Journal:  Int J Hematol       Date:  2016-06-06       Impact factor: 2.490

Review 5.  Novel epigenetic-based therapies useful in cardiovascular medicine.

Authors:  Claudio Napoli; Vincenzo Grimaldi; Maria Rosaria De Pascale; Linda Sommese; Teresa Infante; Andrea Soricelli
Journal:  World J Cardiol       Date:  2016-02-26

6.  Neuroprotective effect of miR-665 against sevoflurane anesthesia-induced cognitive dysfunction in rats through PI3K/Akt signaling pathway by targeting insulin-like growth factor 2.

Authors:  Xihua Lu; Shuaiguo Lv; Yan Mi; Lei Wang; Gensheng Wang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 7.  Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease.

Authors:  Albert Busch; Suzanne M Eken; Lars Maegdefessel
Journal:  Ann Transl Med       Date:  2016-06

Review 8.  The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy.

Authors:  Jianxiang Zhong; Shengbing Wang; Wei-Bin Shen; Sunjay Kaushal; Peixin Yang
Journal:  Pediatr Res       Date:  2017-11-15       Impact factor: 3.756

Review 9.  MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.

Authors:  Palak Shah; Michael R Bristow; J David Port
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 10.  Emerging microRNA biomarkers for acute kidney injury in acute decompensated heart failure.

Authors:  Evelyn M Templeton; Vicky A Cameron; John W Pickering; A Mark Richards; Anna P Pilbrow
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.